Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2018-05-21 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
第四届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the board's approval of a licensing agreement and investment in a target company. The text includes the date of the board meeting, the voting results, and authorization details. There are no financial statements or detailed financial performance data. The document is a formal announcement of a board decision regarding management actions and investments, which fits the category of Board/Management Information (MANG). The document length is short (1136 characters), and it is not a report or presentation but a formal announcement of board resolutions.
2018-05-21 Chinese
关于使用自有资金受让成都金凯生物技术有限公司少数股东股权暨增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's use of its own funds to acquire minority shareholder equity and increase capital in a subsidiary company. It includes details about the transaction, board approval, financial data of the subsidiary, and the impact on the company. The document is structured as a formal announcement with no comprehensive financial statements or detailed financial analysis typical of an annual or interim report. It is not a full financial report but rather a capital transaction update. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3586 characters, which is consistent with an announcement rather than a full report.
2018-05-18 Chinese
第四届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details decisions made by the board regarding capital investment and equity acquisition in subsidiaries. The text includes meeting dates, voting results, and authorization details, but does not contain financial statements or detailed financial performance data. The document is an announcement of board decisions rather than a full management report or financial report. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2018-05-18 Chinese
关于子公司增资Salubris Biotherapeutics, Inc.的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the capital increase (增资) of a subsidiary, Salubris Biotherapeutics, Inc., by the parent company Shenzhen Salubris Pharmaceutical Co., Ltd. It details the investment amount, board approval, purpose, risks, and financial data of the subsidiary. The document is relatively short (2629 characters) and structured as a formal announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report or Annual Report. Instead, it focuses on the financing activity related to the capital increase of a subsidiary. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2018-05-18 Chinese
关于全资子公司投资参股Mercator MedSystems, Inc.的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding an investment by a wholly-owned subsidiary in another company, Mercator MedSystems, Inc. It details the transaction overview, board approval, investment amount, shareholding changes, financial data of the target company, and risk factors. The document is a formal disclosure of a capital investment transaction by the company, including share subscription and strategic rationale. It does not contain financial statements or quarterly/yearly financial results, nor is it a transcript, audit report, or management discussion. It is a capital/financing update about the company's investment activities and shareholding changes in another entity. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing transaction, not just an announcement of a report or a regulatory filing. Confidence is high due to clear transaction and investment details.
2018-05-03 Chinese
第四届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the board's approval of an investment by a wholly-owned subsidiary in Mercator MedSystems, Inc. The text includes meeting details, voting results, and authorization for executing the transaction. There are no financial statements or detailed financial data presented. The document is a formal announcement of a board decision, not a full report or financial filing. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on management decisions rather than financial results or regulatory filings.
2018-05-03 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.